18 September 2019 - - Indian drugmaker Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched Lansoprazole Delayed-Release Capsules USP, 15 mg, an over-the-counter store-brand equivalent of Prevacid 24HR Capsules, in the United States market, as approved by the US Food and Drug Administration (USFDA), the company said.

Dr. Reddy's OTC Lansoprazole Delayed-Release Capsules USP, 15 mg, is an over-the-counter, Proton Pump Inhibitor used to treat frequent heartburn occurring two or more days a week.

The Prevacid 24HR brand and generic had US sales of approximately USD 57m MAT for the most recent twelve months ending in August 2019 according to IRi.

Dr. Reddy's OTC Lansoprazole Delayed-Release Capsules USP, 15 mg, are available in 14, 28 and 42 count sizes.

Prevacid is a registered trademark of Takeda Pharmaceuticals North America, Inc.

Dr. Reddy's Laboratories is an integrated pharmaceutical company.

Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe.

Dr. Reddy's major markets include USA, India, Russia and CIS countries, and Europe.